Highlights ADMA Biologics, Inc.

Equities

ADMA

US0008991046

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
6.74 ^USD	+1.05%		+4.33%	+49.12%

Apr. 02	ADMA Biologics, Inc. Announces Promotion of Kaitlin Kestenberg as Chief Operating Officer	CI
Mar. 26	HC Wainwright Adjusts ADMA Biologics Price Target to $7.50 From $6, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adma Biologics, Inc. Announces FDA Approvals of Extended Room Temperature Storage Conditions for Asceniv & Bivigam	Mar. 11	CI
ADMA Biologics Q4 Net Loss Widens, Revenue Rises; Increases 2024, 2025 Revenue Outlook; Seeks Successor for Chief Financial Officer	Feb. 28	MT
ADMA Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q4 Revenue $73.9M, vs. Street Est of $73M	Feb. 28	MT
ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025	Feb. 28	CI
ADMA Biologics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
ADMA Biologics Implements ADMAlytics AI Program to Bolster Production	Feb. 21	MT
ADMA Biologics, Inc Successfully Implements Innovative AI Program, Named ADMAlytics	Feb. 21	CI
ADMA Biologics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023, Fiscal Year 2024-2025	Jan. 08	CI
ADMA Biologics, Inc. Announces FDA Approval for BIVIGAM in the Pediatric Patient Setting for Those 2 Years of Age and Older	Dec. 12	CI
ADMA Biologics Obtains US FDA Approval for Plasma Collection Center in Maryland	Nov. 16	MT
ADMA Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q3 Revenue $67.3M, vs. Street Est of $62.1M	Nov. 08	MT
ADMA Biologics, Inc. Updates Financial Guidance for the Years 2023, 2024 and 2025	Nov. 08	CI
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q2 Revenue $60.1M, vs. Street Est of $55.5M	23-08-09	MT
ADMA Biologics, Inc. Updates Earnings Guidance for the Full Year 2023, 2024 and 2025	23-08-09	CI
ADMA Biologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
ADMA Biologics, Inc Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA	23-07-19	CI
ADMA Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Earnings Flash (ADMA) ADMA BIOLOGICS Posts Q1 Revenue $56.9M	23-05-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ADMA Biologics, Inc.

Equities

ADMA

US0008991046

Highlights

Filters